The ZUSDURI launch trajectory (73% QoQ growth, 45% repeat prescribers) is the primary catalyst — monitor weekly prescription data and upcoming KOL events for continued acceleration. The EPS miss is minor and likely overshadowed by the revenue beat and patent news. Watch for UGN-103 NDA submission in Q3 2026 as the next major pipeline catalyst.
Price Chart
Executive Summary
UroGen reported Q2 2026 revenue of $72.5M (consensus $63.5M, +14.2% beat), driven by ZUSDURI's $50.4M in revenue (73% QoQ growth). EPS of -$0.28 was a 5.7% miss vs consensus -$0.27. The company raised FY2026 operating expense guidance to $260M-$270M to accelerate ZUSDURI commercialization and pipeline investment. ZUSDURI's accelerating launch trajectory and a new patent allowance extending protection to 2044 are strong positives, but the EPS miss and rising spend temper the outlook. The stock has historically moved strongly on URGN filings (avg T+20 +7.42%).
Key Financial Metrics
Key Facts
- Total revenue $72.5M in Q2 2026, up 199% YoY from $24.2M
- ZUSDURI revenue $50.4M, 73% QoQ growth from Q1 2026
- EPS -$0.28 vs consensus -$0.27 (5.7% miss)
- FY2026 operating expense guidance raised to $260M-$270M from $240M-$250M
- New U.S. patent allowance expected to protect ZUSDURI and UGN-103 into July 2044
- UGN-103 NDA submission on track for Q3 2026; UGN-501 Phase 1 trial expected Q4 2026
- Net loss narrowed to $14.4M from $49.9M in Q2 2025
- Cash and marketable securities $108.0M as of June 30, 2026
Financial Impact
Revenue beat consensus by $9.0M (+14.2%); EPS missed by $0.01 (-5.7%); operating expense guidance raised by $20M at midpoint
Risk Factors
- EPS miss vs consensus despite strong revenue beat
- Rising operating expenses ($260M-$270M guidance) may pressure cash runway
- JELMYTO revenue declined 9% YoY to $22.0M
- Teva settlement allows generic JELMYTO entry on September 15, 2030
- Cash burn: $108.0M at June 30 vs $120.5M at Dec 31, 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-025793 |
| Document: urgn20260730_8k.htm | 0001437749-26-025793 |
| Document: 0001437749-26-025793-index-headers.html | 0001437749-26-025793 |
| Document: 0001437749-26-025793-index.html | 0001437749-26-025793 |
| Document: 0001437749-26-025793.txt | 0001437749-26-025793 |
| 8-K Data (Synthetic) | 0001437749-26-025793 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | Insider Cluster | $45.00 $43.04 | ▼ −4.36% | ▼ −4.02% | $41.73 (−7.27%) |
Aug 20, 2026 6w ago | 8-K | $46.80 $45.50 | ▼ −2.78% | ▼ −3.89% | $41.73 (−10.83%) |
Aug 5, 2026 8w ago | 8-K | $46.43 $49.00 | ▲ +5.54% | ▲ +5.18% | $41.73 (−10.12%) |
Jun 23, 2026 14w ago | 8-K | $35.42 $37.94 | ▲ +7.11% | ▲ +5.41% | $41.73 (+17.81%) |
Jun 2, 2026 17w ago | 8-K | $26.54 $28.18 | ▲ +6.18% | ▲ +9.14% | $41.73 (+57.23%) |
May 6, 2026 21w ago | Press Release | $26.25 $29.80 | ▲ +13.52% | ▲ +12.39% | $41.73 (+58.97%) |
Apr 29, 2026 22w ago | Press Release | $23.34 $23.83 | ▼ −2.10% | ▲ +1.01% | $41.73 (−78.79%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.73 (+119.40%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.73 (+119.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access